$3.5M grant to help Inovio further develop mass vaccine device

04/11/2013 | Genetic Engineering & Biotechnology News

The National Institute of Allergy and Infectious Diseases awarded Inovio Pharmaceuticals a $3.5 million grant to further develop a next-generation DNA vaccine delivery device that can simultaneously administer multiple synthetic vaccines through skin surface electroporation. The device is being co-developed with Chief Scientist Connie Schmaljohn of the Army Medical Research Institute of Infectious Diseases. The goal is to create a device that will allow fast vaccination of U.S. troops and protect the public from pandemic threats.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN